Showing results (71-80 of 145) with videos related to
Sort By:
Pageof 15
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 23, 2023
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosisCavit Boz, Serkan Ozakbas, Murat Terzi, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2025
Disease course after pregnancy in women with progressive multiple sclerosis symptomsJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 19, 2024
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase RegistryAlessio Signori, Marta Ponzano, Tomas Kalincik, et al.The Lancet. Child & Adolescent Health|March 28, 2024
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registriesSifat Sharmin, Izanne Roos, Charles B Malpas, et al.Multiple Sclerosis and Related Disorders|September 2, 2019
Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosisCavit Boz, Murat Terzi, Bilge Özer, et al.Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 7, 2024
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60Yi Chao Foong, Daniel Merlo, Melissa Gresle, et al.Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Risk of secondary progressive multiple sclerosis after early worsening of disabilityWinston Dzau, Sifat Sharmin, Francesco Patti, et al.Pageof 15